Your browser is no longer supported. Please, upgrade your browser.
Immunome, Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own6.60% Shs Outstand11.94M Perf Week-5.96%
Market Cap122.71M Forward P/E- EPS next Y-3.99 Insider Trans8.67% Shs Float8.84M Perf Month-45.52%
Income-20.90M PEG- EPS next Q-0.81 Inst Own22.20% Short Float2.74% Perf Quarter-53.73%
Sales- P/S- EPS this Y-48.70% Inst Trans9.66% Short Ratio2.56 Perf Half Y-41.05%
Book/sh4.59 P/B1.96 EPS next Y-59.50% ROA-39.20% Target Price33.00 Perf Year-43.99%
Cash/sh4.12 P/C2.18 EPS next 5Y- ROE-43.00% 52W Range7.19 - 63.78 Perf YTD-30.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.90% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low25.09% ATR1.28
Employees23 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)31.48 Volatility17.82% 12.00%
OptionableYes Debt/Eq0.00 EPS Q/Q18.60% Profit Margin- Rel Volume0.62 Prev Close9.27
ShortableYes LT Debt/Eq0.00 EarningsNov 16 AMC Payout- Avg Volume94.66K Price8.99
Recom2.00 SMA20-23.61% SMA50-39.11% SMA200-50.41% Volume58,793 Change-3.02%
Oct-29-21Initiated Cantor Fitzgerald Overweight $35
Jan-11-22 09:56AM  
Jan-10-22 04:15PM  
Dec-17-21 07:11AM  
Dec-07-21 07:00AM  
Dec-01-21 01:12PM  
Nov-29-21 07:00AM  
Nov-15-21 05:00PM  
Nov-09-21 04:05PM  
Oct-20-21 08:00AM  
Oct-18-21 10:01AM  
Oct-07-21 09:00AM  
Sep-30-21 04:35PM  
Sep-22-21 04:05PM  
Sep-15-21 04:05PM  
Sep-13-21 11:49AM  
Sep-07-21 07:00AM  
Aug-19-21 04:05PM  
Jul-20-21 08:44AM  
Jul-06-21 07:00AM  
Jun-30-21 07:00AM  
Jun-17-21 07:00AM  
May-29-21 04:33AM  
May-27-21 04:05PM  
May-20-21 10:04AM  
May-12-21 06:00AM  
Apr-26-21 08:09AM  
Apr-20-21 08:00AM  
Mar-30-21 08:00AM  
Mar-25-21 05:14PM  
Mar-23-21 07:00AM  
Feb-18-21 07:06PM  
Feb-03-21 07:00AM  
Feb-01-21 07:00AM  
Jan-17-21 03:53AM  
Dec-10-20 08:00AM  
Nov-17-20 05:53PM  
Oct-13-20 04:05PM  
Oct-02-20 05:53PM  
Oct-01-20 08:23PM  
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAPP MICHAELDirectorSep 13Buy19.9625,962518,202208,742Sep 14 07:28 AM
RAPP MICHAELDirectorSep 10Buy17.8515,500276,675182,780Sep 13 07:52 AM
RAPP MICHAELDirectorSep 09Buy18.1930,450553,774167,280Sep 13 07:52 AM
BARON RICHARD ADirectorAug 18Option Exercise11.382,34326,6632,343Aug 20 06:25 PM
Lefenfeld MichaelDirectorMay 26Buy19.031,33525,40526,872May 26 09:32 PM
RAPP MICHAELDirectorMay 26Buy18.942,30043,562136,830May 26 09:31 PM
Lefenfeld MichaelDirectorMay 25Buy18.442,71550,06525,537May 26 09:32 PM
RAPP MICHAELDirectorMay 25Buy18.3219,303353,631134,530May 26 09:31 PM
Sarma Purnanand DPresident and CEOMay 25Buy18.4110,500193,30510,500May 26 09:28 PM
Lefenfeld MichaelDirectorMay 24Buy17.8060010,68022,822May 26 09:32 PM
RAPP MICHAELDirectorMay 24Buy18.3831,895586,230115,227May 26 09:31 PM
WAGENHEIM PHILIPDirectorMay 24Buy18.3513,500247,725397,397May 26 09:29 PM
LAMATTINA JOHN LDirectorMay 24Buy18.575,440101,02851,828May 26 09:26 PM